Tuesday, 30 April 2019
Interview with STOCKHEAD
Got 90 seconds? Then listen to Leo Lee, the CEO of regenerative medicine company Regeneus, following the appointment of two new board members.
Regeneus news
- Tuesday, 30 April 2019
Regeneus ramps up global focus with addition of industry leaders
Article from STOCKHEAD
Regenerative medicine company Regeneus has secured seasoned industry leaders to its board as it looks to make bigger noise overseas.
- Wednesday, 30 January 2019
Regeneus' newly-appointed CEO Leo Lee discusses strategic plans for growth
Interview with Proactive Investors
Leo Lee, the newly-appointed CEO of Regeneus Ltd (ASX:RGS), speaks to Proactive Investors about the Australian clinical-stage regenerative medicine company's operations, and the wider scientific field.
- Wednesday, 5 September 2018
Several interested parties in Japan
Regeneus has revised expected timing of an osteoarthritis (OA) clinical development licence deal for Progenza in Japan to Q4 CY18 (vs Q218); it is currently in active discussions with several parties. A licence deal would trigger a US$5m milestone payment from partner AGC and would effectively see Progenza commence a Phase II trial in knee OA in Japan.
- Monday, 30 July 2018
Positive clinical trial results for cancer vaccine
Cancer vaccine trial meets primary endpoint of safety with promising signs of immune response
Key points- Primary endpoint of safety and tolerability met
- Immune response detected at all dose levels
- Wednesday, 2 May 2018
Regeneus: leveraging the power of MSC`s
Article from CCRM
Regeneus works to improve people and animals’ lives through the application of proprietary stem cell and immuno-oncology technologies.